Revicki D A, Rentz A M, Dubois D, Kahrilas P, Stanghellini V, Talley N J, Tack J
Center for Health Outcomes Research, MEDTAP International, Inc., Bethesda, MD 20814, USA.
Aliment Pharmacol Ther. 2003 Jul 1;18(1):141-50. doi: 10.1046/j.1365-2036.2003.01612.x.
Patient-based symptom assessments are necessary to evaluate the effectiveness of medical treatments for gastroparesis.
To summarize the development and measurement qualities of the Gastroparesis Cardinal Symptom Index (GCSI), a new measure of gastroparesis-related symptoms.
The GCSI was based on reviews of the medical literature, clinician interviews and patient focus groups. The measurement qualities (i.e. reliability, validity) of the GCSI were examined in 169 gastroparesis patients. Patients were recruited from seven clinical centres in the USA to participate in this observational study. Patients completed the GCSI, SF-36 Health Survey and disability day questions at a baseline visit and again after 8 weeks. Clinicians independently rated the severity of the patients' symptoms, and both clinicians and patients rated the change in gastroparesis-related symptoms over the 8-week study.
The GCSI consists of three sub-scales: post-prandial fullness/early satiety, nausea/vomiting and bloating. The internal consistency reliability was 0.84 and the test-re-test reliability was 0.76 for the GCSI total score. Significant relationships were observed between the clinician-assessed symptom severity and the GCSI total score, and significant associations were found between the GCSI scores and SF-36 physical and mental component summary scores and restricted activity and bed disability days. Patients with greater symptom severity, as rated by clinicians, reported greater symptom severity on the GCSI. The GCSI total scores were responsive to changes in overall gastroparesis symptoms as assessed by clinicians (P = 0.0002) and patients (P = 0.002).
The findings of this study indicate that the GCSI is a reliable and valid instrument for measuring the symptom severity in patients with gastroparesis.
基于患者的症状评估对于评估胃轻瘫医学治疗的有效性是必要的。
总结胃轻瘫主要症状指数(GCSI)的发展及测量质量,这是一种新的胃轻瘫相关症状测量方法。
GCSI基于医学文献综述、临床医生访谈和患者焦点小组制定。在169例胃轻瘫患者中检验了GCSI的测量质量(即信度、效度)。患者从美国七个临床中心招募以参与这项观察性研究。患者在基线访视时以及8周后再次完成GCSI、SF-36健康调查和残疾日问题。临床医生独立评定患者症状的严重程度,临床医生和患者都对8周研究期间胃轻瘫相关症状的变化进行评定。
GCSI由三个子量表组成:餐后饱胀/早饱、恶心/呕吐和腹胀。GCSI总分的内部一致性信度为0.84,重测信度为0.76。观察到临床医生评定的症状严重程度与GCSI总分之间存在显著相关性,并且在GCSI评分与SF-36身体和心理成分汇总评分以及受限活动和卧床残疾天数之间发现显著关联。临床医生评定症状严重程度较高的患者在GCSI上报告的症状严重程度也较高。GCSI总分对临床医生(P = 0.0002)和患者(P = 0.002)评定的总体胃轻瘫症状变化有反应。
本研究结果表明,GCSI是一种可靠且有效的测量胃轻瘫患者症状严重程度的工具。